Kowalski J, Okopien B, Madej A, Makowiecka K, Zielinski M, Kalina Z, Herman Z S
Department of Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Int J Clin Pharmacol Ther. 2001 Feb;39(2):48-52. doi: 10.5414/cpp39048.
Hyperlipoproteinemia is one of the factors that are involved in the development of atherosclerosis. One of the mechanisms through which these high plasma lipid levels trigger the formation of atherosclerotic lesions is a change in the expression of adhesion molecules on endothelial and smooth muscle cells. The aim of this study was to evaluate the plasma levels of soluble intracellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) in patients with Type IIa (HLP-IIa) and IIb (HLP-IIb) hyperlipoproteinemias.
Twenty patients with HLP-IIa, 20 patients with HLP-IIb and 23 control subjects were studied. To accurately evaluate adhesion molecule levels, we excluded those hyperlipemic patients and control subjects who had an inflammatory disease.
Plasma sICAM-1, sVCAM-1 and MCP-1 levels were measured by the ELISA method.
sVCAM-1 levels in HLP-IIa and HLP-IIb patients (535 +/- 27 ng/ml and 545 +/- 22 ng/ml, respectively) did not differ significantly from those in the control group (558 +/- 20 ng/ml). sICAM-1 levels were significantly higher in patients with HLP-IIa and HLP-IIb (279 +/- 10 ng/ml and 322 +/- 12 ng/ml, respectively) compared to the control group (226 +/- 10 ng/ml). MCP-1 levels were significantly higher in HLP-IIa and HLP-IIb patients (151 +/- 12 pg/ml vs 154 +/- 12 pg/ml, respectively) compared to healthy controls (98 +/- 4 pg/ml). sICAM-1 levels in the HLP-IIb group were significantly higher than in the HLP-IIa group.
The results of the study suggest that lipid abnormalities affect the levels of adhesion molecules and chemokines in plasma.
高脂蛋白血症是参与动脉粥样硬化发展的因素之一。这些高血浆脂质水平触发动脉粥样硬化病变形成的机制之一是内皮细胞和平滑肌细胞上黏附分子表达的改变。本研究的目的是评估IIa型（HLP-IIa）和IIb型（HLP-IIb）高脂蛋白血症患者血浆中可溶性细胞间黏附分子-1（sICAM-1）、可溶性血管细胞黏附分子-1（sVCAM-1）和单核细胞趋化蛋白-1（MCP-1）的水平。
研究了20例HLP-IIa患者、20例HLP-IIb患者和23例对照受试者。为准确评估黏附分子水平，我们排除了患有炎症性疾病的高脂血症患者和对照受试者。
采用酶联免疫吸附测定（ELISA）法检测血浆sICAM-1、sVCAM-1和MCP-1水平。
HLP-IIa和HLP-IIb患者的sVCAM-1水平（分别为535±27 ng/ml和545±22 ng/ml）与对照组（558±20 ng/ml）相比无显著差异。与对照组（226±10 ng/ml）相比，HLP-IIa和HLP-IIb患者的sICAM-1水平显著更高（分别为279±10 ng/ml和322±12 ng/ml）。与健康对照组（98±4 pg/ml）相比，HLP-IIa和HLP-IIb患者的MCP-1水平显著更高（分别为151±12 pg/ml对154±12 pg/ml）。HLP-IIb组的sICAM-1水平显著高于HLP-IIa组。
研究结果表明脂质异常会影响血浆中黏附分子和趋化因子的水平。
